Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Jasper Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Jasper Therapeutics, Inc.’s stock price such as:

• Jasper Therapeutics, Inc.’s current stock price and volume
• Why Jasper Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for JSPR from analysts
• JSPR’s stock price momentum as measured by its relative strength

About Jasper Therapeutics, Inc. (JSPR)

Before we jump into Jasper Therapeutics, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.

Want to learn more about Jasper Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Jasper Therapeutics, Inc..

What Caused Jasper Therapeutics, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Jasper Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Jasper Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Jasper Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Jasper Therapeutics, Inc. (JSPR) by visiting AAII Stock Evaluator.

Relative Price Strength of Jasper Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Jasper Therapeutics, Inc. has a weighted four-quarter relative price strength of -34.40%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how Jasper Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Jasper Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Jasper Therapeutics, Inc.’s stock price is $0.630, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Jasper Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.